SAGE THERAPEUTICSCS INC
SAGE THERAPEUTICSCS INC
Aktie · US78667J1088 · SAGE · A117WF (XNMS)
Übersicht Finanzkennzahlen
6,85 USD
1,03 % 0,07 USD
NASDAQ/NMS (GLOBAL MARKET) (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 20:00

Aktuelle Kurse von SAGE THERAPEUTICSCS INC

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
SAGE
USD
06.06.2025 20:00
6,85 USD
6,78 USD
+1,03 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % 6,04 % -0,15 % -9,63 % 22,10 % -36,40 % -81,08 %

Firmenprofil zu SAGE THERAPEUTICSCS INC Aktie

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Investierte Fonds

Folgende Fonds haben in investiert: SAGE THERAPEUTICSCS INC investiert:

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in Mio
93,46
Anteil (%)
0,22 %

Unternehmensdaten

Name SAGE THERAPEUTICSCS INC
Firma Sage Therapeutics, Inc.
Symbol SAGE
Website https://www.sagerx.com
Heimatbörse XNMS NASDAQ/NMS (GLOBAL MARKET)
WKN A117WF
ISIN US78667J1088
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Barry E. Greene
Marktkapitalisierung 460 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,4 T
Adresse 215 First Street, 02142 Cambridge
IPO Datum 2014-07-18

Ticker Symbole

Name Symbol
Frankfurt SG7.F
NASDAQ SAGE

Weitere Aktien

Investoren die SAGE THERAPEUTICSCS INC die halten, haben auch folgende Aktien im Depot:
AMAZON.CO INC
AMAZON.CO INC Aktie
CHINA OUTFITTERS H.
CHINA OUTFITTERS H. Aktie
CISCO SYSTEMS INC
CISCO SYSTEMS INC Aktie
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Aktie
DWS GLOBAL WATER LD
DWS GLOBAL WATER LD Fonds
EUR
EUR Crypto
LBBW STUFENZINS 19/26
LBBW STUFENZINS 19/26 Anleihe
MICRON TECHNOLOGIESLOGY INC
MICRON TECHNOLOGIESLOGY INC Aktie
MICROSOFT CORP
MICROSOFT CORP Aktie
PROCTER GAMBLE CORP
PROCTER GAMBLE CORP Aktie
QUALCOMM INC
QUALCOMM INC Aktie
TESLA INC
TESLA INC Aktie
VERTEX PHARMACEUTICALS INC
VERTEX PHARMACEUTICALS INC Aktie
William Blair Small Cap Growth Fund Class N
William Blair Small Cap Growth Fund Class N Fonds
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025